Abstract
Objective: To evaluate the safety, pharmacodynamics (PD), efficacy, and pharmacokinetics of ACE-083 in patients with facioscapulohumeral muscular dystrophy (FSHD).
Background: ACE-083 is a locally-acting therapeutic based on follistatin that binds myostatin and other muscle regulators. It has been shown to increase muscle mass and force in neuromuscular disease mouse models and to increase muscle mass in healthy volunteers.
Design/Methods: In this study, Part 1 is dose-escalation, open-label, and Part 2 is placebo-controlled. ACE-083 was injected into either the tibialis anterior (TA) or biceps brachii muscle every 3 weeks for 5 doses. Total muscle volume (TMV) and intramuscular fat fraction (FF) were assessed by MRI (Dixon method) on Days 1, 43, 106, and 141. PD assessments include timed motor function tests, gait analysis, and the FSHD-Health Index.
Results: Data were available for this abstract as of Sept 22, 2017 and are shown for patients treated with 150 mg unilaterally into the TA muscle (n=6). Median (range) age was 46.5 yr (42–52), duration of symptoms was 26.5 yr (5–35), and FF was 36.5% (13.6–68.7). Increases in TMV and decreases in FF were seen by Day 43. At Day 106, mean (SD) percent change on the treated side in TMV was 6.7% (8.9) and absolute change in FF (%) was −4.8% (6.4). In the contralateral untreated TA muscle, these changes were −0.5 (7.7) and −0.8 (1.1), respectively. Related adverse events included transient injection site pain/discomfort and myalgia; there were no serious AEs. Dose escalation is ongoing.
Conclusions: ACE-083 was well-tolerated in patients with FSHD and encouraging results were seen for changes in muscle volume and fat fraction in the initial dose cohorts. These preliminary results support further studies of ACE-083 in neuromuscular disorders; current ongoing studies include FSHD and Charcot-Marie-Tooth disease.
Disclosure: Dr. Statland has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Strongbridge, Acceleron, Regeneron, and Sanofi. Dr. Amato has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Strongbridge Pharmaceuticals. Dr. Bravver has nothing to disclose. Dr. Campbell has nothing to disclose. Dr. Elman has nothing to disclose. Dr. Johnson has received personal compensation for consulting, serving on a scientific advisory board, speakering, or other activities with AMO Pharma, AveXis and Strongbridge Pharma. Dr. Johnson has received compensation in an editorial capacity for Neurology Genetics. Dr. Johnson has received research support from Biogen Idec, Cytokinetics, AMO Pharma, AveXis and Ionis Pharmaceuticals. Dr. Joyce has nothing to disclose. Dr. Karam has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with alnylam, alexion, sanofigenzyme,nufactor, soleohealth, optioncare. Dr. Kissel has received research support from Novartis, Biomarin, Cytokinetics, CSL Behring, Avexis, Ionis Pharmaceuticals, Quintiles, Axelacare. Dr. Korngut has nothing to disclose. Dr. O'Ferrall has nothing to disclose. Dr. Manousakis has nothing to disclose. Dr. Pestronk has nothing to disclose. Dr. Shieh has nothing to disclose. Dr. Tawil has nothing to disclose. Dr. Leneus has nothing to disclose. Dr. Miller has nothing to disclose. Dr. Sherman has nothing to disclose. Dr. Glasser has nothing to disclose. Dr. Attie has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Versartis.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.